Ad
related to: feminizing hormone therapy results in cancer treatment
Search results
Results from the WOW.Com Content Network
The effect of feminizing hormone therapy on fertility is not clear, but it is known that testosterone suppression can prevent sperm production. [299] The age of starting and stopping hormone therapy seems to be a significant factor, but no direct causation has been found between length of treatment and ability to reproduce. [300] [301]
Gender-affirming hormone therapy (GAHT), also called hormone replacement therapy (HRT) or transgender hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity.
t. e. Masculinizing hormone therapy, also known as transmasculine hormone therapy or female-to-male (or FTM) hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. [1][2][3] It is a common type of ...
Though hormone replacement therapy has been a popular form of treatment for decades, used to offset symptoms of menopause in women and andropause (aging-related hormone changes) in men, hormone ...
Included in the guidelines are sections on purpose and use of the WPATH SOC, the global applicability of the WPATH SOC, the difference between gender nonconformity and gender dysphoria, epidemiology, treatment of children, adolescents and adults, mental health, hormone replacement therapy (masculinizing or feminizing; HRT), reproductive health ...
Hormone replacement therapy (HRT) is primarily concerned with alleviating gender dysphoria in transgender people. [17] Hormone therapy targets the secondary sex characteristics. Trans women typically use feminizing therapy, the goal of which is to develop female characteristics while suppressing male characteristics.
Any trans climbers using testosterone or spironolactone (a feminizing hormone therapy) would have to apply for a Therapeutic Use Exemption (TUE) from the United States Anti-Doping Agency, which ...
Nilutamide is used in prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue at a dosage of 300 mg/day (150 mg twice daily) for the first 4 weeks of treatment, and 150 mg/day thereafter. [27][36] It is not indicated as a monotherapy in prostate cancer. [27]
Ad
related to: feminizing hormone therapy results in cancer treatment